Biohaven Pharmaceutical has reported positive topline results from the Phase III BHV3000-303 or Study 303 clinical trial of zydis.

The trial is designed to investigate the efficacy and safety of rimegepant zydis orally dissolving tablet (ODT) compared with placebo for the acute treatment of migraines.

Results demonstrated that Study 303 met its co-primary registrational objectives of pain freedom and suppression of most bothersome symptom (MBS) at two hours using a single dose of rimegepant zydis ODT.

It was also found that patients who received zydis experienced the onset of pain relief with numerical separation from placebo as early as 15 minutes, while this difference was statistically significant at 60 minutes.

“These results reinforce the potential of rimegepant to be an important new and differentiated option for the acute treatment of migraine.”

Around 85% of the patients treated with the drug did not use any rescue medications during the trial.

The safety and tolerability of rimegepant was reported to be similar to that observed in Studies 301 and 302.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biohaven Pharmaceutical CEO Vlad Coric said: “Fast-acting and long-lasting pain relief in an easy to use formulation is important to patients.

“Rimegepant provides these characteristics and we believe is the first oral CGRP receptor antagonist to report superiority over placebo on pain relief and return to normal functioning by 60 minutes.

“These results, combined with the previous data from the two prior Phase III trials, reinforce the potential of rimegepant to be an important new and differentiated option for the acute treatment of migraine.”

Study 303 features a double-blind, randomised, outpatient trial setting.

It enrolled 1,375 patients across sites in the US and treated them with a single 75mg dose of rimegepant zydis ODTor a matching placebo.